Business Context and Reporting Period
This Form 6-K filing by RedHill Biopharma Ltd. (RDHL) covers the month of May 2023, with the report dated May 15, 2023. The filing incorporates a press release regarding a regulatory notification from the Nasdaq Stock Market. RedHill is a specialty biopharmaceutical company focused on gastrointestinal and infectious diseases, with commercial products including Talicia and Aemcolo, and a pipeline of late-stage clinical candidates.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on a listing compliance issue rather than financial performance data.
Material Changes and Listing Status
- NASDAQ Deficiency: The Company received a notification on May 9, 2023, stating it is not in compliance with the minimum Market Value of Publicly Held Shares (MVPHS) requirement.
- Requirement: Nasdaq Listing Rule 5450(b)(3)(C) mandates a minimum MVPHS of US$15 million.
- Deficiency Trigger: The deficiency occurred because the MVPHS remained below the threshold for 30 consecutive business days.
- Current Status: The notification does not currently impact the listing or trading of the Company's securities.
Outlook, Risks, and Contingencies
Compliance Period: RedHill has 180 calendar days (until November 6, 2023) to regain compliance. To resolve the matter, the MVPHS must close at US$15 million or more for a minimum of ten consecutive business days during this period.
Consequences of Non-Compliance: If the Company fails to regain compliance by the deadline, its securities will be subject to delisting. Alternatively, the Company may apply to transfer its securities to the Nasdaq Capital Market.
Risk Factors: The filing highlights risks related to the commercialization of products, the success of clinical trials (specifically for RHB-107 and opaganib), the ability to secure non-dilutive funding, and market conditions affecting sales.
Investor Verification Checklist
- Verify the current Market Value of Publicly Held Shares (MVPHS) to assess proximity to the US$15 million threshold.
- Monitor the Company's stock price performance over the next 180 days to determine if the 10-day consecutive compliance window is met.
- Review the Company's Annual Report on Form 20-F (filed April 28, 2023) for detailed financial data and liquidity status not included in this filing.
- Assess the progress of key clinical programs (RHB-107, opaganib, RHB-104) as potential catalysts for market value recovery.
- Check for any subsequent announcements regarding a potential transfer to the Nasdaq Capital Market.